$RMD (ResMed Inc.)

$RMD {{ '2016-08-18T12:37:42+0000' | timeago}} • Announcement

$RMD said it seeks injunction, in the U.S. International Trade Commission, banning importation of Fisher & Paykel Simplus full face mask, Eson nasal mask and Eson 2 nasal mask. In San Diego court, $RMD asserts Fisher & Paykel's masks infringe $RMD's patents relating to modular mask systems, headgear design, and cushion design.

$RMD {{ '2018-01-22T22:00:14+0000' | timeago}} • Announcement

Hurt by one-time charges related to the US tax reform, $RMD reported 88% decline in 2Q18 earnings to $9.5MM, or 7 cents per share. Excluding these charges, net income rose 37% to $1 during the quarter. Meanwhile, revenue jumped 13% to $601.3MM.

$RMD {{ '2018-01-22T21:48:59+0000' | timeago}} • Infographic

$RMD ResMed Inc. Earnings AlphaGraphic: Q2 2018 Highlights

$AMGN {{ '2018-01-19T13:28:13+0000' | timeago}} • Announcement

The European Commission (EC) has granted marketing authorization for MVASI from $AMGN and $AGN. MVASI is the first biosimilar bevacizumab approved by the EC and is approved for the treatment of certain types of cancers.

$GE {{ '2018-01-17T20:56:28+0000' | timeago}} • Announcement

$GE Transportation signed two contracts, valued at over $900MM, with Kazakhstan's state-run railroad Kazakhstan Temir Zholy, as part of its long-term commitment to develop the country's railway infrastructure. The contracts include the delivery of 300 shunter locomotives and an 18-year service agreement.

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$HOLX {{ '2018-01-16T13:05:50+0000' | timeago}} • Announcement

$HOLX said its CE-marked Aptima HIV-1 Quant Dx assay has been awarded World Health Organization (WHO) prequalification for in vitro diagnostic. The Aptima HIV-1 Quant Dx assay is the first HIV-1 viral load assay with a dual claim for both diagnosis and treatment monitoring.

$HOLX {{ '2018-01-11T21:23:15+0000' | timeago}} • Announcement

Medical technology company $HOLX has elected Namal Nawana to its board of directors, effective immediately. Nawana was formerly the CEO of Alere, Inc. Prior to that, he served Johnson & Johnson in various leadership roles, including Worldwide President of DePuy Synthes Spine.

$SYK {{ '2018-01-09T17:21:37+0000' | timeago}} • Announcement

$SYK said that for 4Q17 its preliminary results are of net sales growth of 10% to $3.5Bil, while for FY17, its net sales grew 9.9% to $12.4Bil. Excluding the impact of foreign currency & acquisitions, net sales rose 8.1% and 7.1% in 4Q17 and FY17. For 2018, $SYK expects modest headwinds that will be manageable within its overall financial targets.

$HRC {{ '2018-01-09T17:07:14+0000' | timeago}} • Announcement

$HRC announced its preliminary 1Q18 revenue. For this period, the company expects worldwide revenue of approx $670MM, an increase of 5% YoY. Core revenue increased approx 2%, exceeding the company's previously issued guidance of flat core revenue growth.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$HOLX {{ '2018-01-08T13:10:32+0000' | timeago}} • Announcement

Medical technology company $HOLX said it is currently looking for net revenues of about $791MM for the first quarter of 2018, higher than $775MM-$790MM the company had estimated earlier. The latest guidance represents an 8% YoY growth, reflecting the effect of divestiture of Hologic’s blood screening business and acquisition of Cynosure.

$HOLX {{ '2018-01-03T13:10:03+0000' | timeago}} • Announcement

$HOLX said the MyoSure MANUAL device, which was designed to simplify tissue removal procedures regardless of setting, has received CE mark in Europe. The MyoSure MANUAL device joins the MyoSure suite of gynecologic surgical products that offer simple and effective solutions to resect and remove tissue.

$TFX {{ '2018-01-02T14:56:01+0000' | timeago}} • Announcement

$TFX completed its senior leadership transition. Effective Jan. 1, 2018, Liam Kelly, who was previously President & COO, assumed the position of President & CEO. Mr. Kelly succeeds Benson Smith, who retired as CEO, effective Dec. 31, 2017. Mr. Smith will continue to serve as non-executive Chairman of the Board.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$CNI {{ '2017-12-22T19:58:54+0000' | timeago}} • Announcement

Railroad company $CNI has decided to purchase 200 new locomotives from $GE over the next three years. Production of the locomotives will commence next year at the GE facility in Texas, and the units are expected to be delivered in 2018, 2019 and 2020. The order includes Tier-4 and Tier -3 Evolution Series locomotives.

$AGN {{ '2017-12-21T14:38:43+0000' | timeago}} • Announcement

$AGN and its partner $PRTK announced that FDA accepted to review Seysara, an investigational drug for treating acne. Allergan, which has the U.S. rights of developing and marketing Seysara, expects FDA to take action on this in 2H18. Paratek retains the non-U.S. rights. In March 2017, Allergan announced positive results from Seysara Phase 3 trials.

$AGN {{ '2017-12-18T22:26:29+0000' | timeago}} • Announcement

Robert Stewart, COO of $AGN will resign from his role. He has been named as the CEO of the newly formed Amneal Pharmaceuticals, effective Jan. 25, 2018. Following Rob's departure, Wayne Swanton, SVP, Global Operations has been promoted as EVP, Global Operations of Allergan.

$AGN {{ '2017-12-18T22:14:14+0000' | timeago}} • Announcement

$AGN and its development partner Gedeon Richter Plc reported positive results from phase 3 study of cariprazine, which is used to treat the bipolar depression. Allergan plans to file the New Drug Application to the FDA in 2H18.

$GE {{ '2017-12-18T14:51:55+0000' | timeago}} • Announcement

Airborne Wireless Network (ABWN) entered into a Support Agreement on Dec. 14, 2017 with GE Aviation, one of $GE Business Units. ABWN anticipates that this relationship should significantly accelerate the development of ABWN's proprietary Hybrid Radio and Free-Optics Communications System to be demonstrated CY18.

$IPXL {{ '2017-12-18T13:05:53+0000' | timeago}} • Announcement

Amneal Pharmaceuticals LLC and $IPXL said Robert Stewart will join Amneal as President, effective Jan. 25, 2018. Stewart most recently served as COO of $AGN. After completion of combination of Amneal and $IPXL, Stewart will become President and CEO of the combined company, to be named Amneal Pharmaceuticals Inc., and will become a BoD member.

Recent Transcripts

RMD (ResMed Inc.)
Monday, January 22 2018 - 9:30pm
CMD (Cantel Medical Corp.)
Thursday, December 7 2017 - 4:00pm
TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
CNCE (Concert Pharmaceuticals, Inc.)
Thursday, November 9 2017 - 1:30pm
GMED (Globus Medical, Inc.)
Wednesday, November 8 2017 - 10:30pm
HOLX (Hologic Inc.)
Wednesday, November 8 2017 - 9:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, November 7 2017 - 10:00pm
HAE (Haemonetics Corporation)
Tuesday, November 7 2017 - 1:00pm
PTLA (Portola Pharmaceuticals, Inc.)
Monday, November 6 2017 - 9:30pm
HRC (Hill-Rom Holdings, Inc.)
Friday, November 3 2017 - 12:00pm
TFX (Teleflex Incorporated)
Thursday, November 2 2017 - 12:00pm
STE (Steris Plc)
Wednesday, November 1 2017 - 2:00pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
CRY (CryoLife Inc.)
Tuesday, October 31 2017 - 12:00pm
RMD (ResMed Inc.)
Thursday, October 26 2017 - 8:30pm
SYK (Stryker Corporation)
Thursday, October 26 2017 - 8:30pm
VAR (Varian Medical Systems, Inc.)
Wednesday, October 25 2017 - 9:00pm
EW (Edwards Lifesciences Corp.)
Tuesday, October 24 2017 - 9:00pm
MMM (3M Company)
Tuesday, October 24 2017 - 1:00pm
PHG (Koninklijke Philips N.V)
Monday, October 23 2017 - 8:00am

AlphaGraphics you may like